23,549 results match your criteria Anticancer Research[Journal]



Anticancer Res 2022 May;42(5):2803

View Article and Full-Text PDF

Co-treatment of Low Dose Pacritinib, a Phase III Jak2 Inhibitor, Greatly Increases Apoptosis of P-gp Over-expressing Cancer Cells With Multidrug Resistance.

Anticancer Res 2022 May;42(5):2433-2442

School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea

Background/aim: The over-expression of P-glycoprotein (P-gp) is a major mechanism underlying multidrug resistance (MDR). Co-treatment with Janus kinase 2 (Jak2) inhibitors sensitizes P-gp-over-expressing drug-resistant cancer cells. In this study, we evaluated pacritinib, a Jak2 inhibitor currently in phase III clinical trials. Read More

View Article and Full-Text PDF

Early Metabolic Changes in 1H-MRSI Predictive for Survival in Patients With Newly Diagnosed High-grade Glioma.

Anticancer Res 2022 May;42(5):2665-2673

Division of Radiation Oncology, University of Alberta, Edmonton, Canada;

Background: The purpose of this study was to evaluate the association of specific threshold values for changes in metabolic metrics measured from 1H magnetic resonance spectroscopic imaging (MRSI) to survival of patients with high-grade glioma treated with multimodality therapy.

Patients And Methods: Forty-four patients with newly diagnosed high-grade glioma were prospectively enrolled. Serial MRI and MRSI scans provided measures of tumor choline, creatine, and N-acetylaspartate (NAA). Read More

View Article and Full-Text PDF

Handgrip Strength Predicts Poorly the Surgical Outcome or Length of Hospitalization in Patients With Surgically Operated Oral Cancer.

Anticancer Res 2022 May;42(5):2771-2774

Department of Oral and Maxillofacial Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Background/aim: Handgrip strength has been used to evaluate the potential of elderly patients to survive different medical conditions or procedures, or to predict the nutritional status and length of hospitalization. The aim of this study was to evaluate the use of handgrip strength as a predictor of the length of hospitalization and need for prolonged intensive care in patients with oral malignancies requiring surgical resection and simultaneous primary reconstruction with microvascular free flap.

Patients And Methods: This is a retrospective study of 37 head and neck carcinoma patients operated between 2012 and 2014 who had undergone a handgrip force test. Read More

View Article and Full-Text PDF

Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study.

Anticancer Res 2022 May;42(5):2783-2790

Department of Gastroenterological Surgery, Kanazawa University, Kanazawa, Japan.

Background/aim: To evaluate the impact of prophylactic administration of pegfilgrastim in esophageal cancer (EC) patients treated with chemotherapy consisted of docetaxel, cisplatin, and fluorouracil (DCF).

Patients And Methods: Among 102 patients who received neoadjuvant or induction DCF for primary advanced EC, 65 received prophylactic pegfilgrastim and 37 did not. The association of pegfilgrastim with adverse events and clinicopathological outcomes was retrospectively analyzed. Read More

View Article and Full-Text PDF

Clinical Outcomes of Esophagectomy and Chemoradiotherapy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma.

Anticancer Res 2022 May;42(5):2791-2795

Department of Radiology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.

Background/aim: Surgical resection and chemoradiotherapy (CRT) can be performed as additional treatments for superficial esophageal cancer after endoscopic resection, but the selection criteria vary depending on the institution. We retrospectively evaluated the outcomes of patients with endoscopically resected superficial esophageal cancer treated with surgical resection and CRT at our institution.

Patients And Methods: The outcomes of 67 cases of additional treatment after endoscopic resection of superficial esophageal cancer, excluding adenocarcinoma, performed at our hospital from January 2000 to June 2017 were compared (30 cases in the surgery group and 37 cases in the CRT group). Read More

View Article and Full-Text PDF

Optimal Organ for Patient-derived Xenograft Model in Pancreatic Cancer and Microenvironment that Contributes to Success.

Anticancer Res 2022 May;42(5):2395-2404

Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.

Background: We aimed to investigate the difference in engraftment rates depending on the transplant site for a patient-derived xenograft (PDX) of pancreatic ductal adenocarcinoma (PDAC) and the effects of the microenvironment on engraftment.

Materials And Methods: Frozen cancer tissues from PDAC tumors were used, and tumor fragments were directly implanted into the subcutaneous, orthotopic pancreas, peritoneum, and liver of X-linked severe combined immunodeficiency (XSCID) rats. We assessed the success of engraftment in each organ. Read More

View Article and Full-Text PDF

Poorly Differentiated Thyroid Carcinoma: Single Institution Series of Outcomes.

Anticancer Res 2022 May;42(5):2531-2539

Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, U.S.A.;

Background And Aim: Poorly differentiated thyroid cancer (PDTC) is a rare but aggressive subtype of thyroid cancer that portends a poor prognosis. There remains a paucity of literature on PDTC outcomes. The aim of our study was to evaluate outcomes of PDTC in our tertiary care facility. Read More

View Article and Full-Text PDF

Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for -mutated Non-small Cell Lung Cancer.

Anticancer Res 2022 May;42(5):2583-2590

Department of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Background/aim: Real-world data on the clinical outcomes of first-line osimertinib treatment for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations is lacking. This study aimed to reveal the treatment outcomes and prognostic factors of osimertinib as first-line therapy in clinical practice settings.

Patients And Methods: We retrospectively evaluated clinical outcomes of patients with EGFR-mutated NSCLC treated with osimertinib as first-line therapy across 12 institutions in Japan between August 2018 and March 2020. Read More

View Article and Full-Text PDF

Circulating Tumor Cells Derived from Advanced Hepatocellular Carcinoma Rapidly Develop Resistance to Cytotoxic Chemotherapy.

Anticancer Res 2022 May;42(5):2479-2486

Liver Research Center, Chang Gung Memorial Hospital Linkou Main Branch, Taoyuan, Taiwan, R.O.C.;

Background/aim: Clinically, some cancer patients develop drug resistance after receiving a few courses of chemotherapy, or even worse, completely lack therapeutic response. Prediction of treatment response before administration is of value to oncologists. This study aimed to evaluate the feasibility of drug sensitivity tests for circulating tumor cells (CTCs) isolated from patients with advanced hepatocellular carcinoma (HCC). Read More

View Article and Full-Text PDF

High Receptor-interacting Serine/Threonine-protein Kinase 3 (RIP3) Expression Serves as an Independent Poor Prognostic Factor for Triple-negative Breast Carcinoma.

Anticancer Res 2022 May;42(5):2753-2761

Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University College of Medicine, Seoul, Republic of Korea;

Background/aim: Receptor-interacting serine/threonine-protein kinase 3 (RIP3) is a key component related to tumor necrosis factor-dependent necroptosis. RIP3 has been known to be a predictive biomarker in many types of carcinomas. We aimed to investigate whether RIP3 expression is correlated with clinicopathological characteristics and the outcomes of patients with breast carcinoma. Read More

View Article and Full-Text PDF

Surgical Indications for Huge Hepatocellular Carcinoma.

Anticancer Res 2022 May;42(5):2573-2581

Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Background/aim: This study aimed to retrospectively analyse adverse predictors to identify patients with huge hepatocellular carcinoma who were not appropriate candidates for hepatic resection.

Patients And Methods: From 551 patients with hepatocellular carcinoma who underwent hepatectomy between 1992 and 2019, 92 were diagnosed with huge hepatocellular carcinoma (diameter >10 cm) and 115 were diagnosed with large hepatocellular carcinoma (diameter=5-10 cm). Clinical features and overall and disease-free survival rates were compared between the two groups. Read More

View Article and Full-Text PDF

Time to Onset of Bendamustine-associated Skin Damage Using the Spontaneous Reporting System.

Anticancer Res 2022 May;42(5):2737-2741

Department of Education and Research Center for Pharmacy Practice, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyotanabe, Japan;

Background/aim: Bendamustine-associated skin damage occurs frequently in Japan and can have a profound impact on health-related quality of life. To our knowledge, there are no reports on the timing of skin damage caused by bendamustine. This study assessed trends in and the time to onset of skin damage caused by bendamustine using the Japanese Adverse Drug Reaction Reporting Database (JADER). Read More

View Article and Full-Text PDF

Contribution of Genotypes to Colorectal Cancer in Taiwan.

Anticancer Res 2022 May;42(5):2375-2382

Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.;

Background/aim: 5-methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR) is responsible for folate metabolism, and we aimed to investigate its genetic role in colorectal cancer (CRC) among Taiwanese.

Materials And Methods: A total of 362 cases and 362 controls were recruited and their MTRR rs1801394 (A66G) and rs1532268 (C524T) genotypes were examined. The behavioral factors and clinicalpathological factors were also analyzed. Read More

View Article and Full-Text PDF

Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial.

Anticancer Res 2022 May;42(5):2683-2687

Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.

Background: Safety of combination chemotherapy using platinum and fluorouracil has not been evaluated adequately for advanced gastric cancer (AGC) in elderly patients.

Patients And Methods: We initiated a phase II study to evaluate the efficacy and safety of capecitabine plus oxaliplatin (CapeOX) as first-line therapy for patients with AGC aged ≥70 years. Planned assessment of toxicity was made upon recruitment of the first 20 patients. Read More

View Article and Full-Text PDF

Impact of Histological Features on Adjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Carcinoma.

Anticancer Res 2022 May;42(5):2645-2655

Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan;

Background/aim: This study evaluated the efficacy of adjuvant chemotherapy (AC) for intraductal papillary mucinous carcinoma (IPMC).

Patients And Methods: We retrospectively analyzed patients who underwent pancreatectomy for invasive IPMC from January 2007 to June 2020. We evaluated outcomes of AC in the entire cohort and in patients with known prognostic factors. Read More

View Article and Full-Text PDF

Risk Factors for Xerostomia Following Radiotherapy of Head-and-Neck Cancers.

Anticancer Res 2022 May;42(5):2657-2663

Department of Radiation Oncology, University of Lübeck, Lübeck, Germany;

Background/aim: Many head-and-neck cancer patients receive radiotherapy, which may be associated with significant toxicities. Xerostomia is considered one of the most debilitating late adverse events. This study was performed to identify risk factors for xerostomia. Read More

View Article and Full-Text PDF

Impact of the Platelet-to-Lymphocyte Ratio as a Biomarker for Esophageal Squamous Cell Carcinoma.

Anticancer Res 2022 May;42(5):2775-2782

Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan.

Background/aim: Esophageal squamous cell carcinoma (ESCC) is a deadly malignant disease. This study examined whether the platelet-to-lymphocyte ratio (PLR) can be used as a biomarker to evaluate prognosis in patients with advanced ESCC following neoadjuvant chemotherapy (NAC) and undergoing minimally invasive esophagectomy (MIE).

Patients And Methods: We examined 174 patients between January 2010 and December 2015 at the Kobe University. Read More

View Article and Full-Text PDF

The Effect of Asparagus Extract on Pancreatic Cancer: An Intriguing Surprise.

Anticancer Res 2022 May;42(5):2425-2432

Department of Surgery, The Affiliated Hospital of Xiangnan University, Chenzhou, P.R. China;

Background: Pancreatic cancer is the most lethal digestive cancer and the fourth overall cause of cancer death in the US. Asparagus, a widely consumed savory vegetable, is a rich source of antioxidants, saponins, vitamins, and minerals. In recent years, it has been shown that components of asparagus have anticancer effects on endometrial adenocarcinoma, and in prostate, breast, and colon cancer. Read More

View Article and Full-Text PDF

Impact of Infectious Complications on Survival and Recurrence of Patients With Stage II/III Colorectal Cancer: A Multicenter Retrospective Study.

Anticancer Res 2022 May;42(5):2763-2769

Department of Surgery, Yokohama City University, Yokohama, Japan.

Background/aim: Postoperative complications are associated with increased recurrence in colorectal cancer (CRC). We investigated the impact of infectious complications on the recurrence of CRC and overall survival after curative surgery in a single study group.

Patients And Methods: In total, 1,668 patients who underwent radical resection for CRC in Yokohama City University, Yokohama Minami Kyosai Hospital, and Kanagawa Cancer Center between 2011 and 2019 were reviewed. Read More

View Article and Full-Text PDF

Investigating miRNA-related Pathways Contributing to Kidney Cancer Pathogenesis.

Anticancer Res 2022 May;42(5):2355-2362

Department of Laboratory Medicine, and the Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada;

Background/aim: Renal cell carcinoma is one of the most common types of cancer worldwide. Understanding tumor pathogenesis is important in developing better treatment. Micro RNAs (miRNAs) are key players in controlling cancer behavior. Read More

View Article and Full-Text PDF

Expression of LncRNAs in HPV-induced Carcinogenesis and Cancer Cachexia: A Study in K14-HPV16 Mice.

Anticancer Res 2022 May;42(5):2443-2460

Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/[email protected] (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Porto, Portugal;

Aim: To evaluate the expression of lincRNA-p21, H19, EMX2OS, SNHG12 and MALAT1 in a mouse model of human papillomavirus 16 (HPV16)-induced carcinogenesis and cachexia.

Materials And Methods: Chest skin, ear, tongue, penis and gastrocnemius muscle samples from wild-type mice (HPV-) and K14-HPV16 male mice (HPV+) were collected to evaluate the expression of the selected lncRNAs using real-time PCR (qPCR).

Results: In chest skin and ear, H19, SNHG12, EMX2OS and lincRNA-p21 were down-regulated in HPV+ versus HPV- mice. Read More

View Article and Full-Text PDF

The and Copy-number-variation Influence the -signature-score in Wild-type Luminal Type Breast Cancer.

Anticancer Res 2022 May;42(5):2277-2288

Department of Clinical Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan

Background/aim: The TP53-signature is a multi-gene signature that can predict TP53 structural mutations. It has presented remarkable ability to predict the prognosis of early-stage breast cancer. However, some samples presented discordance with the signature status and structure status. Read More

View Article and Full-Text PDF

The Implication of X-Linked Genetic Polymorphisms in Susceptibility and Sexual Dimorphism of Cancer.

Anticancer Res 2022 May;42(5):2261-2276

Laboratory of Medical Biology - Genetics, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece;

The X-chromosome is implicated in cancer development through various mechanisms, including X-inactivation defects, loss of heterozygosity, and germline and somatic alterations of X-linked genes. Sex is a key factor which influences cancer susceptibility as many cancer types show sexual dimorphism in their incidence. The aim of this review was to summarize the germline genetic polymorphisms lying on the X-chromosome that have been associated with cancer susceptibility and to evaluate their possible implication in cancer-related sexual dimorphism. Read More

View Article and Full-Text PDF

Bevacizumab-based Salvage Chemotherapy Improves Survival Outcomes for Patients With Brain Metastasis from Ovarian Cancer.

Anticancer Res 2022 May;42(5):2637-2644

Department of Gynecology, Chiba University Hospital, Chiba, Japan.

Background/aim: Brain metastases from ovarian cancer remain rare and the appropriate treatment is unknown. We investigated survival outcomes following salvage chemotherapy before and after bevacizumab approval to evaluate the efficacy of bevacizumab in patients with brain metastasis from ovarian cancer.

Patients And Methods: We investigated 23 consecutive patients with brain metastasis from ovarian cancer at our hospital between 2001 and 2020. Read More

View Article and Full-Text PDF

Chemotherapy-induced Reversion of Mutant to Wild-type in Metastatic Colorectal Cancer.

Anticancer Res 2022 May;42(5):2625-2635

Department of Surgery, Yokohama City University, Yokohama, Japan.

Background/aim: Secondary mutation of mutated RAS, induced by chemotherapy, is thought to be rare. However, introduction of liquid biopsy (LB) has made it possible to monitor RAS status in patients' plasma throughout the course of chemotherapy for metastatic colorectal cancer (mCRC), and disappearance of the RAS mutation (RAS-mt), i.e. Read More

View Article and Full-Text PDF

Proton Pump Inhibitors Ameliorate Capecitabine-induced Hand-Foot Syndrome in Patients With Breast Cancer: A Retrospective Study.

Anticancer Res 2022 May;42(5):2591-2598

Department of Pharmacy, Osaka University Hospital, Suita, Japan.

Background/aim: Hand-foot syndrome (HFS) is the most common adverse event associated with capecitabine, and its pathogenesis is known to be associated with inflammation. Proton pump inhibitors (PPIs) reportedly exert anti-inflammatory effects; however, the impact of PPIs on capecitabine-induced HFS needs to be clarified in the clinical setting. In the present study, we retrospectively investigated the efficacy and safety of PPIs in patients with breast cancer receiving capecitabine. Read More

View Article and Full-Text PDF

Prognostic Value of Peritoneal Cancer Index After Complete Cytoreductive Surgery in Advanced Ovarian Cancer.

Anticancer Res 2022 May;42(5):2541-2551

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Department of Clinical Science Lund, Skåne University Hospital, Lund University, Lund, Sweden.

Background/aim: Residual disease (RD) after primary debulking surgery (PDS) is a prognostic factor for survival in advanced ovarian cancer (AOC). This study aimed to examine whether the tumor extent affects overall survival (OS) and progression-free survival (PFS) in AOC patients treated with PDS.

Patients And Methods: A total of 118 patients treated with PDS were included. Read More

View Article and Full-Text PDF

Dimethyl Fumarate Induces Apoptosis Inhibiting NF-κB and STAT3 Signaling in Adult T-cell Leukemia/Lymphoma Cells.

Anticancer Res 2022 May;42(5):2301-2309

Division of Hematology & Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan

Background/aim: Adult T-cell leukemia (ATL) is a peripheral T lymphocytic malignancy caused by human T-cell leukemia virus type 1 (HTLV-1) infection. Despite treatment that includes novel agents that have been developed, most of ATL patients relapse and acquire multidrug resistance. As a result, the creation of newer agents is critical. Read More

View Article and Full-Text PDF

Changes in Lysophospholipid Components in Ulcerative Colitis and Colitis-associated Cancer.

Anticancer Res 2022 May;42(5):2461-2468

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Background: In recent years, it has become clear that, in addition to normal cytokines, phospholipid mediators play an important role in the development, growth, infiltration, and metastasis of cancer and in the cancer microenvironment. A phospholipid analysis method using tandem mass spectrometry (LC-MS/MS) with high detection sensitivity has enabled quantification of phospholipids, even when using a very small sample. To date, we had applied this MS technology to colorectal cancer tissue. Read More

View Article and Full-Text PDF